TWIST BIOSCIENCE CORPORATION |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 47 USD | +1.06% |
|
+11.00% | +27.59% |
| May. 03 | Sector Update: Health Care Stocks Mixed Late Afternoon | MT |
| May. 03 | Sector Update: Health Care Stocks Mixed in Afternoon Trading | MT |
Valuation
| Fiscal Period: September | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 775.4 | 3,393 | 5,273 | 1,986 | 1,163 | 2,708 | - | - |
| Enterprise Value (EV) 1 | 645 | 3,108 | 4,808 | 1,608 | 876.4 | 2,531 | 2,558 | 2,582 |
| P/E ratio | -6.09 x | -21.3 x | -34 x | -8.72 x | -5.63 x | -15.6 x | -18.4 x | -23.3 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 14.3 x | 37.7 x | 39.8 x | 9.76 x | 4.74 x | 8.93 x | 7.42 x | 6.21 x |
| EV / Revenue | 11.9 x | 34.5 x | 36.3 x | 7.9 x | 3.58 x | 8.35 x | 7.01 x | 5.92 x |
| EV / EBITDA | -6.28 x | -28 x | -33.5 x | -7.37 x | -4.67 x | -17 x | -21.2 x | 181 x |
| EV / FCF | -6.28 x | -20.4 x | -34.5 x | -7.11 x | -5.15 x | -26.2 x | -31.8 x | -48.4 x |
| FCF Yield | -15.9% | -4.89% | -2.9% | -14.1% | -19.4% | -3.82% | -3.15% | -2.07% |
| Price to Book | 4.3 x | 10.2 x | 9.12 x | 2.52 x | 1.87 x | 5.28 x | 6.01 x | 6.93 x |
| Nbr of stocks (in thousands) | 32,472 | 44,663 | 49,292 | 56,364 | 57,396 | 58,226 | - | - |
| Reference price 2 | 23.88 | 75.97 | 107.0 | 35.24 | 20.26 | 46.50 | 46.50 | 46.50 |
| Announcement Date | 12/11/19 | 11/23/20 | 11/22/21 | 11/18/22 | 11/17/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: September | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 54.38 | 90.1 | 132.3 | 203.6 | 245.1 | 303.3 | 364.7 | 436.1 |
| EBITDA 1 | -102.7 | -110.9 | -143.5 | -218.3 | -187.8 | -149.1 | -120.4 | 14.24 |
| EBIT 1 | -108.8 | -117.6 | -153.3 | -234.8 | -217.2 | -185.9 | -156.4 | -110.5 |
| Operating Margin | -200.15% | -130.5% | -115.81% | -115.33% | -88.6% | -61.29% | -42.9% | -25.34% |
| Earnings before Tax (EBT) 1 | -107.4 | -139.5 | -154 | -228.3 | -203.5 | -174.6 | -153.5 | -102.7 |
| Net income 1 | -107.7 | -139.9 | -152.1 | -217.9 | -204.6 | -175.9 | -152.9 | -103.4 |
| Net margin | -197.98% | -155.31% | -114.94% | -107.02% | -83.48% | -58.01% | -41.92% | -23.72% |
| EPS 2 | -3.920 | -3.570 | -3.150 | -4.040 | -3.600 | -2.978 | -2.529 | -1.993 |
| Free Cash Flow 1 | -102.7 | -152.1 | -139.3 | -226.2 | -170.3 | -96.67 | -80.46 | -53.34 |
| FCF margin | -188.83% | -168.84% | -105.27% | -111.14% | -69.46% | -31.88% | -22.06% | -12.23% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 12/11/19 | 11/23/20 | 11/22/21 | 11/18/22 | 11/17/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: Septiembre | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 42.02 | 48.13 | 56.11 | 57.31 | 54.24 | 60.18 | 63.74 | 66.95 | 71.5 | 75.3 | 77.21 | 79.48 | 83.49 | 90.74 | 91.01 |
| EBITDA 1 | -55.62 | -56.83 | -56.72 | - | -43.47 | - | -52.29 | -41.61 | -38.81 | -40.58 | -35 | -33.8 | - | - | - |
| EBIT 1 | -58.77 | -60.8 | -61.16 | -56.87 | -48.76 | -62.83 | -60.78 | -50.11 | -46.98 | -48.89 | -46.3 | -43.16 | -38.55 | -38.28 | -37.15 |
| Operating Margin | -139.86% | -126.34% | -109% | -99.24% | -89.9% | -104.41% | -95.36% | -74.85% | -65.7% | -64.92% | -59.96% | -54.3% | -46.17% | -42.18% | -40.82% |
| Earnings before Tax (EBT) 1 | -55.97 | -60.82 | -60.67 | -50.82 | -41.75 | -58.48 | -56.77 | -46.46 | -42.89 | -45.15 | -45.77 | -43.3 | -40.72 | -37.99 | -37.41 |
| Net income 1 | -45.56 | -60.67 | -60.52 | -51.12 | -41.82 | -59.16 | -57.4 | -46.24 | -43.01 | -45.49 | -46 | -43.48 | -41.42 | -38.18 | -37.08 |
| Net margin | -108.44% | -126.06% | -107.85% | -89.2% | -77.1% | -98.3% | -90.05% | -69.08% | -60.15% | -60.41% | -59.57% | -54.71% | -49.62% | -42.08% | -40.75% |
| EPS 2 | -0.9100 | -1.130 | -1.080 | -0.9100 | -0.7400 | -1.040 | -1.010 | -0.8100 | -0.7500 | -0.7900 | -0.7683 | -0.7202 | -0.6333 | -0.6267 | -0.6200 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/4/22 | 5/5/22 | 8/5/22 | 11/18/22 | 2/3/23 | 5/5/23 | 8/4/23 | 11/17/23 | 2/2/24 | 5/2/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: Septiembre | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 130 | 285 | 464 | 379 | 286 | 177 | 150 | 125 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -103 | -152 | -139 | -226 | -170 | -96.7 | -80.5 | -53.3 |
| ROE (net income / shareholders' equity) | -89.1% | -57.3% | -33.2% | -31.8% | -29% | -32.8% | -35.2% | -31.4% |
| ROA (Net income/ Total Assets) | -51.4% | -47.8% | -27.6% | -26.2% | -23.5% | -26.2% | -27.9% | -22% |
| Assets 1 | 209.3 | 292.9 | 550.5 | 831.7 | 868.9 | 672 | 548.8 | 470.2 |
| Book Value Per Share 2 | 5.550 | 7.460 | 11.70 | 14.00 | 10.80 | 8.810 | 7.730 | 6.710 |
| Cash Flow per Share 2 | -3.200 | -3.630 | -2.330 | -2.310 | -2.510 | -1.400 | -1.030 | -0.5100 |
| Capex 1 | 14.8 | 9.87 | 27.1 | 102 | 27.8 | 14 | 24.5 | 22.9 |
| Capex / Sales | 27.13% | 10.95% | 20.45% | 50.04% | 11.33% | 4.62% | 6.72% | 5.26% |
| Announcement Date | 12/11/19 | 11/23/20 | 11/22/21 | 11/18/22 | 11/17/23 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
46.5
USD
Average target price
43.38
USD
Spread / Average Target
-6.72%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +27.59% | 2.71B | |
| -2.32% | 92.59B | |
| +3.68% | 41.43B | |
| -11.19% | 33.49B | |
| -19.23% | 14.62B | |
| -8.95% | 12.77B | |
| -11.34% | 11.58B | |
| -43.53% | 11.35B | |
| +3.75% | 8.97B | |
| -6.32% | 8.3B |
- Stock Market
- Equities
- TWST Stock
- Financials Twist Bioscience Corporation